- Accueil
- tpex
- Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
4.7 (499) · € 37.99 · En Stock
A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma - Ju - 2023 - MedComm - Wiley Online Library
Cancers, Free Full-Text
Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer, BMC Cancer
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial
Systemic Treatment Sequencing and Prediction of First-line Therapy Outcomes in Recurrent or Metastatic Head and Neck Cancer
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer, BMC Cancer
Comprehensive treatment of squamous cell cancer of head and neck: Chinese expert consensus 2013
Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck - ScienceDirect
Cancers, Free Full-Text
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108)
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised
Established treatment concepts for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSSC)
PDF) First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2
